Allon Therapeutics, Inc. Releases First Quarter Operating Results

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - May 11, 2006) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, reported today in its first quarter 2006 operating results that it continued to achieve important milestones in its drug development programs. Achievements during the quarter included: Publication of results from a Phase Ia human clinical trial showing AL-208 to be safe and well tolerated in the target population for the treatment of mild cognitive impairment (MCI) associated with coronary artery bypass graft surgery (CABG).
MORE ON THIS TOPIC